12:49 PM
 | 
Apr 27, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Aprea reports Phase Ib/II response data for APR-246 in MDS

Aprea Therapeutics AB (Stockholm, Sweden) said APR-246 plus Vidaza azacitidine led to an overall response rate (ORR) of 100%, including six complete responses and two marrow complete responses, in eight evaluable patients with myelodysplastic syndrome (MDS) in a...

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >